Drug Eluting Versus Covered Stent for Femoropopliteal Artery Lesions: Results of the ULTIMATE Study

Objective: Stent grafts (SG) and drug eluting stents (DES) have emerged to combat intimal hyperplasia. It remains unclear which type of stent yields superior outcomes in femoropopliteal (FP) arterial lesions. This study compared the clinical data between the VIABAHN SG and the Eluvia DES two years after endovascular treatment. Methods: In this retrospective multicentre study, 504 cases with a lesion length > 10 cm treated either with SG or DES were analysed. Ankle brachial index (ABI) measurements were conducted before and after the endovascular procedure, and every three months thereafter. When the ABI dropped >= 0.15 compared with the baseline value, a duplex ultrasound was conducted to check stent patency. The outcome measures were stent patency rates, freedom from target lesion revascularisation (TLR), stent thrombosis, and acute limb ischaemia (ALI) accompanying loss of patency rates. Propensity score matching (PSM) was performed to adjust for confounding baseline characteristics. Results: PSM extracted 219 limbs in the SG group and 109 limbs in the DES group. Compared with the SG group, the DES group had statistically significantly higher rates of freedom from TLR (86.0 +/- 4.2% vs. 73.1 +/- 4.8%, p = .040), and ALI accompanying loss of patency (98.9 +/- 1.1% vs. 93.5 +/- 1.8%, p = .029) at two years. Primary patency (75.9 +/- 5.9% vs. 69.5 +/- 5.9%, p = .087) and freedom from stent thrombosis (90.4 +/- 3.3% vs. 81.2% +/- 3.0%, p = .11) were not statistically significantly different. For lesions <= 15 cm, primary patency in the DES group was statistically significantly better than the SG group. Conclusion: FP lesions treated with Eluvia DES had a higher primary patency rate in lesions <= 15 cm, freedom from clinically driven TLR and ALI accompanying loss of patency than the VIABAHN SG.

Automated summary

This study compared the clinical data between VIABAHN stent grafts and Eluvia drug eluting stents in femoropopliteal arterial lesions. The results showed that Eluvia DES had a higher primary patency rate, freedom from target lesion revascularization, and freedom from acute limb ischaemia accompanying loss of patency, compared to VIABAHN stent grafts, especially in lesions <= 15 cm.